Bio

Drew is a managing director in our healthcare team. He has more than 15 years of M&A experience across the life sciences and healthcare sectors gained in both advisory and principal roles. He has worked on over 40 closed transactions, including several landmark deals. Before joining Alantra, Drew spent seven years at AstraZeneca, where he was a senior member of the Business Development and M&A team. He was involved in global transactions with an aggregate value in excess of $50bn, including strategic M&A, joint ventures, carve-outs, product divestitures, collaborations, structured investments and licenses. Drew’s experience covers the full span of the product life cycle, as well as various therapeutic areas and modalities. Prior to AstraZeneca, Drew was a member of the Healthcare & Life Sciences team at EY advising companies and investors across multiple sub-sectors with a particular focus on biopharmaceuticals, outsourced service providers (CROs, CDMOs) and healthcare IT. Whilst at EY, Drew was also seconded to Novartis’ global M&A team in Basel.